M33 Growth I L.P.'s Form 4 filing
Starling Oncology, Inc. (DFPH) · filed Jun 9, 2025
- Accession no.
- 0001213900-25-052626
- Filed
- Jun 9, 2025, 4:15 PM ET
- Trade date
- Jun 5, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $2.29M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| M33 Growth I L.P.CIK 0001718621 | Director, 10% Owner |
| Toi M, LLCCIK 0001892968 | Director, 10% Owner |
| M33 Growth I GP LLCCIK 0001894303 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2025 | Common Stock | SSaleDisposed | −673,676 | $3.05 | −$2,054,711.8 | 13,950,557 | Direct | |
| Jun 5, 2025 | Common Stock | SSaleDisposed | −76,324 | $3.05 | −$232,788.2 | 1,272,724 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.